{"gene":"CXCL12","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":1996,"finding":"Targeted disruption of PBSF/SDF-1 (CXCL12) in mice resulted in perinatal lethality with severe reduction of B-cell progenitors in fetal liver and bone marrow, reduction of myeloid progenitors specifically in bone marrow but not fetal liver, and cardiac ventricular septal defect, establishing CXCL12 as essential for B-cell lymphopoiesis, bone-marrow myelopoiesis, and cardiogenesis.","method":"Targeted gene disruption (knockout mouse), histological and progenitor cell analyses","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean germline knockout with defined developmental phenotypes, replicated across multiple organ systems in a single rigorous study; foundational paper widely confirmed","pmids":["8757135"],"is_preprint":false},{"year":2009,"finding":"CXCR7 constitutively heterodimerizes with CXCR4 as efficiently as homodimerization; CXCR7 expression induces conformational rearrangements within preassembled CXCR4/Gαi complexes and impairs CXCR4-promoted Gαi-protein activation and calcium responses to CXCL12, thereby modulating CXCL12-mediated chemotaxis in T cells.","method":"BRET/FRET energy transfer assays, calcium flux assays, chemotaxis assays in primary T cells and transfected cell lines, CXCL12/CXCR7 blocking experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (energy transfer, calcium flux, chemotaxis) in a single lab; mechanistic pathway established","pmids":["19380869"],"is_preprint":false},{"year":2010,"finding":"CXCR7 acts as a specific scavenger receptor for CXCL12 (and CXCL11), mediating constitutive ligand internalization and targeting chemokine cargo for degradation; CXCR7 continuously cycles between the plasma membrane and intracellular compartments independently of ligand, and CXCR7-dependent chemokine degradation is not saturated with increasing ligand concentrations.","method":"Ligand internalization assays, degradation assays in mammalian cells and zebrafish, live cell imaging, in situ studies in mouse heart valves and human umbilical vein endothelium","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (internalization, degradation, cycling, in vivo validation) across cell lines, primary tissue, and two species","pmids":["20161793"],"is_preprint":false},{"year":2006,"finding":"CXCL12-induced cell migration requires a PAK1/2 → p38α MAPK → MAPKAP-K2 → HSP27 signaling pathway; pharmacological inhibition or genetic ablation of p38α, RNAi against MAPKAP-K2, or RNAi against HSP27 each blocked CXCL12-induced cell migration.","method":"Pharmacological inhibition (SB203580, BIRB0796), genetic p38α knockout mice, RNA interference (MAPKAP-K2, HSP27), macrophage migration assay, HeLa cell migration assay","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal genetic and pharmacological interventions across cell types and mouse models converge on the same pathway","pmids":["16574378"],"is_preprint":false},{"year":2011,"finding":"DNA hypomethylation of the CXCL12 promoter in rheumatoid arthritis synovial fibroblasts (RASFs) drives increased CXCL12 expression relative to osteoarthritis SFs; CXCL12 stimulation of RASFs increases MMP expression via CXCR7 (not CXCR4), as demonstrated by CXCR7 siRNA knockdown.","method":"Bisulfite sequencing, McrBC methylation assay, 5-azacytidine demethylation, ELISA, CXCR7 siRNA transfection, real-time PCR for MMPs","journal":"Genes and immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (methylation analysis, demethylation treatment, receptor-specific siRNA) in a single lab","pmids":["21753787"],"is_preprint":false},{"year":2012,"finding":"CXCL12 promotes lymphangiogenesis and lymphatic endothelial cell (LEC) migration and tube formation via CXCR4, activating intracellular Akt and Erk phosphorylation; the CXCL12-CXCR4 axis promotes lymphangiogenesis independently of the VEGFR-3 pathway in vivo.","method":"In vitro LEC migration and tubule formation assays, phosphorylation assays (Akt, Erk), specific antagonist treatment, in vivo lymphangiogenesis model, orthotopic breast cancer model with anti-CXCL12 antibody treatment","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo mechanistic experiments with pathway inhibitors in a single lab","pmids":["22932666"],"is_preprint":false},{"year":2014,"finding":"CXCR7/ACKR3 expressed on venule endothelium regulates circulating CXCL12 plasma levels; genetic deletion or pharmacological inhibition of CXCR7 caused pronounced increases in plasma CXCL12 levels and impaired leucocyte migration toward CXCL12.","method":"Genetic CXCR7 deletion, pharmacological CXCR7 inhibition, plasma CXCL12 ELISA, leucocyte migration assay, immunohistochemistry, complementary protein detection techniques in human and mouse tissues","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological approaches with functional readout, replicated across species and tissues in a single study","pmids":["24116850"],"is_preprint":false},{"year":2016,"finding":"CXCL12 regulates angiogenesis through CXCR4 via mTORC2 (but not mTORC1); CXCR4 signaling activates mTORC2 through a G-protein- and PI3K-dependent pathway as indicated by Akt Ser473 phosphorylation; mTORC2-dependent glycolytic regulator PFKFB3 is required for microvascular sprouting.","method":"mTOR complex-specific siRNA knockdown, pharmacological inhibition, Akt phosphorylation assays, 3D in vitro angiogenesis model, mouse tumor angiogenesis model","journal":"Angiogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple independent siRNAs and drugs targeting mTOR complexes with in vitro and in vivo confirmation in a single lab","pmids":["27106789"],"is_preprint":false},{"year":2013,"finding":"Crystal structure of hu30D8 Fab/CXCL12α complex combined with mutational analysis revealed that residues Asn44/Asn45 of CXCL12α and part of the RFFESH region are a 'hot spot' required for CXCL12α binding to both CXCR4 and CXCR7.","method":"X-ray crystallography (Fab/CXCL12α complex), site-directed mutagenesis, cell surface binding assay, cell migration assay","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure plus mutagenesis identifying functional binding determinants, single lab but orthogonal structural and functional methods","pmids":["23812669"],"is_preprint":false},{"year":2017,"finding":"Antitubulin chemotherapeutics (paclitaxel/vincristine) increase CXCL12 expression in spinal dorsal horn neurons via STAT3-p300 interaction: STAT3 phosphorylation increases its binding to the CXCL12 gene promoter and interaction with acetyltransferase p300, leading to enhanced histone H4 acetylation at the CXCL12 promoter and increased transcription; CXCL12 then signals via CXCR4 (not CXCR7) to potentiate nociceptive synaptic transmission.","method":"Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), adeno-associated virus Cre-mediated STAT3 knockout, STAT3 inhibitor, siRNA, transgenic CXCL12 knockout mice, neutralizing antibody, electrophysiology (mEPSC recording), behavioral assays","journal":"Pain","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reconstitution-level mechanistic dissection using CoIP, ChIP, genetics, pharmacology, and electrophysiology; multiple orthogonal methods in one study","pmids":["28072604"],"is_preprint":false},{"year":2019,"finding":"CXCL12 acts via CXCR4 to activate the GSK3β/β-catenin(Thr120)/TCF21 signaling pathway, reducing TCF21-dependent transcription of ABCA1 and inhibiting ABCA1-mediated cholesterol efflux from macrophages; CXCR4 knockdown/inhibition blocked these effects.","method":"Luciferase reporter assay, chromatin immunoprecipitation, Western blotting (phospho-GSK3β, phospho-β-catenin), CXCR4 siRNA/inhibitor, cholesterol efflux assay, lentivirus CXCL12 overexpression in Apoe-/- mice","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase, ChIP, phosphorylation assays, receptor-specific knockdown, and in vivo confirmation in a single lab","pmids":["31662443"],"is_preprint":false},{"year":2019,"finding":"Platelet-derived CXCL12 activates CXCR4 on platelets to trigger a signaling cascade involving Bruton's tyrosine kinase (Btk), leading to integrin αIIbβ3 activation, platelet aggregation, and granule release; platelet-specific CXCL12 deficiency in mice limits arterial thrombosis and neointimal lesion formation without increasing bleeding time.","method":"Platelet-specific CXCL12 knockout mice, CXCR4 inhibition, Btk phosphorylation assays, platelet aggregation assays under static and arterial flow conditions, carotid artery injury model, tail bleeding time assay, peptide (i[VREY]4) inhibition","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific knockout with defined in vivo thrombosis phenotype, mechanistic pathway defined by pharmacological and genetic approaches, multiple functional readouts","pmids":["35313337"],"is_preprint":false},{"year":2015,"finding":"CXCL12 signaling through CXCR4 regulates the formation of productive immunological synapses in T cells; CXCR4 downregulation or blockade impairs actin polymerization at the T cell–APC contact site, alters MTOC polarization and IS structure, reduces T cell/APC contact duration and T cell activation (CD25, CD69, IL-2); this effect is mediated through Gi and JAK1/JAK2 kinases.","method":"CXCR4 siRNA knockdown, CXCR4 blocking antibody, confocal microscopy of actin and MTOC, flow cytometry (CD25, CD69), IL-2 mRNA measurement, pharmacological JAK1/2 inhibition","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic (siRNA) and pharmacological approaches with multiple orthogonal functional readouts in a single lab","pmids":["25917087"],"is_preprint":false},{"year":2019,"finding":"HMGB1 forms a heterocomplex with CXCL12 (reduced/all-thiol form) that signals via CXCR4 to recruit inflammatory cells; diflunisal binds directly to both HMGB1 and CXCL12 and disrupts this heterocomplex, specifically inhibiting the chemotactic activity of HMGB1 in vitro and in vivo without inhibiting TLR4-dependent (disulfide-HMGB1) responses.","method":"NMR binding assays, in vitro chemotaxis assays, in vivo inflammatory recruitment models, direct binding assays between diflunisal, HMGB1, and CXCL12","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structural binding data plus in vitro and in vivo functional validation of heterocomplex disruption; multiple orthogonal methods in one study","pmids":["31418171"],"is_preprint":false},{"year":2020,"finding":"CXCL12 rescues synaptodendritic spine density and cognitive flexibility via CXCR4-dependent stimulation of the Rac1/PAK actin polymerization pathway in layer II/III pyramidal neurons of the medial prefrontal cortex; CXCL12 preferentially regulates plastic thin spines.","method":"Rodent model of neuroinflammation (HAND), intracranial CXCL12 administration, CXCR4 antagonist treatment, confocal imaging of dendritic spines, Rac1/PAK pathway inhibition, behavioral cognitive flexibility assays","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo model with receptor-specific antagonism and pathway inhibition; single lab with multiple functional readouts","pmids":["31971513"],"is_preprint":false},{"year":2013,"finding":"CXCL12/SDF-1 facilitates optic nerve regeneration in mature retinal ganglion cells (RGCs) via CXCR4-dependent stimulation of the PI3K/AKT/mTOR pathway (not JAK/STAT3); CXCL12 exerts disinhibitory effects toward myelin that are blocked by a CXCR4 antagonist or PI3K/mTOR inhibition.","method":"In vitro RGC neurite growth assay on laminin and myelin, CXCR4 antagonist treatment, PI3K/mTOR pathway inhibitors, JAK/STAT3 inhibitors, intravitreal CXCL12 injection, in vivo optic nerve crush model, mTOR activity assay","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo experiments with receptor-specific and pathway-specific pharmacological tools; single lab","pmids":["23578489"],"is_preprint":false},{"year":2017,"finding":"CXCL12/CXCR4 autocrine signaling in esophageal cancer stem cells activates the ERK1/2 pathway to maintain high invasion and metastasis capacity; loss-of-function (shRNA, inhibitors) and gain-of-function strategies both confirmed CXCL12's role.","method":"CXCR4 shRNA knockdown, CXCR4 inhibitors, CXCL12 loss-of-function and gain-of-function, ERK1/2 phosphorylation assay, in vitro invasion/migration assays, in vivo metastasis model","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — complementary loss- and gain-of-function with pathway readout in vitro and in vivo; single lab","pmids":["28193907"],"is_preprint":false},{"year":2020,"finding":"CXCL12/CXCR4 axis induces glioma cell invadopodia formation and invasion by stimulating Arg kinase (ABL2)-mediated phosphorylation of cortactin at Y421; Arg silencing blocked CXCL12-induced cortactin phosphorylation and invadopodium formation, and CXCL12 could not induce invasion in Arg-knockdown cells.","method":"Arg siRNA knockdown, cortactin phosphorylation assay, co-immunoprecipitation of Arg and cortactin, invadopodia formation assay, invasion assay","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with multiple functional readouts (phosphorylation, invadopodia, invasion) and CoIP; single lab","pmids":["32035133"],"is_preprint":false},{"year":2011,"finding":"In zebrafish, a single amino acid exchange distinguishes two Cxcl12 paralogs by determining their differential affinity for duplicated Cxcr4 receptors, establishing the molecular basis for primordial germ cell (PGC) preferential migration toward one paralog; this represents protein subfunctionalization via receptor-ligand affinity.","method":"Zebrafish genetics, site-directed mutagenesis of CXCL12 paralogs, PGC migration assays, receptor binding/affinity measurements","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis identifying single amino acid determinant of receptor selectivity with in vivo functional validation; single lab","pmids":["21693511"],"is_preprint":false},{"year":2016,"finding":"Oncogenic JAK2 cooperates with CXCL12/CXCR4 signaling to enhance chemotactic responses in hematopoietic cells through increased PI3K signaling; JAK2 inhibition reduces CXCL12/CXCR4-induced chemotaxis, and primary myelofibrosis patient cells show increased CXCL12-induced chemotaxis compared to controls.","method":"MPL-W515L expression, JAK2 siRNA knockdown, JAK2 chemical inhibitors, chemotaxis assays with human cell lines and primary CD34+ cells from MPN patients, PI3K pathway readouts","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological convergence on pathway with primary patient cell validation; single lab","pmids":["28903325"],"is_preprint":false},{"year":2015,"finding":"CXCL12 (SDF-1) induces CD9 tetraspanin expression in satellite cell-derived myoblasts, bone marrow-derived mesenchymal stem cells, and embryonic stem cells through CXCR4 (not CXCR7); CXCR4 silencing blocked the CD9 upregulation effect, and CD9 upregulation enhances cell migration and fusion with myoblasts during muscle regeneration.","method":"In vivo skeletal muscle injury model (rat and Pax7-/- mice), CXCR4/CXCR7 siRNA knockdown, flow cytometry for CD9, in vitro migration and fusion assays with multiple stem cell types","journal":"Stem cell research & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-specific siRNA with in vitro and in vivo validation across multiple cell types; single lab","pmids":["25890097"],"is_preprint":false},{"year":2024,"finding":"CXCL12-secreting senescent fibroblasts (p16high) in aged bladder accumulate as cancer-associated fibroblasts and promote tumor growth; CXCL12 secreted by these cells inhibits CD8+ naïve T cell differentiation into cytotoxic T cells and attracts MDSCs, creating an immunosuppressive tumor microenvironment; elimination of p16high cells or CXCL12 inhibition suppressed tumor growth in vivo.","method":"Genetically modified mouse models (p16-reporter), single-cell RNA sequencing, p16high cell elimination, CXCL12 signaling inhibition, humanized mouse HCC model, bispecific antibody (anti-CXCL12/PD1)","journal":"Nature aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic and pharmacological interventions with mechanistic scRNA-seq; single lab with multiple orthogonal approaches","pmids":["39251867"],"is_preprint":false},{"year":2008,"finding":"CXCL12 has structurally distinct binding sites for its receptor CXCR4 and for glycosaminoglycans (heparan sulfate); these sites do not overlap, and different CXCL12 isoforms display different GAG-binding abilities, suggesting GAG binding positions CXCL12 in tissues to maintain haptotactic gradients while leaving the receptor-binding domain free.","method":"Structural analysis, NMR mapping of GAG-binding and receptor-binding epitopes, isoform-specific binding assays","journal":"Carbohydrate research","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — NMR structural mapping with functional binding assays for receptor vs. GAG sites; review-style paper but cites direct structural evidence","pmids":["18334249"],"is_preprint":false}],"current_model":"CXCL12 (SDF-1/PBSF) is a constitutively expressed CXC chemokine that signals primarily through the G-protein-coupled receptor CXCR4 and the atypical scavenger receptor CXCR7/ACKR3 to regulate cell migration, survival, and development; CXCR4 activates divergent intracellular cascades including Gαi-dependent signaling (calcium flux, chemotaxis), PI3K/Akt/mTOR, ERK1/2, JAK/STAT, PAK-p38α-MAPKAP-K2-HSP27, Rac1/PAK actin polymerization, and Btk-integrin αIIbβ3 pathways depending on cellular context; CXCR7 constitutively internalizes and degrades CXCL12 to regulate its extracellular availability and can heterodimerize with CXCR4 to dampen Gαi signaling; CXCL12's activity is further regulated by binding to glycosaminoglycans via a site distinct from its receptor-binding domain, by post-translational modifications (proteolysis, citrullination, nitration), and by promoter methylation; in development, CXCL12/CXCR4 signaling is essential for B lymphopoiesis, bone-marrow myelopoiesis, cardiogenesis, and neuronal migration, as established by knockout mouse phenotypes."},"narrative":{"mechanistic_narrative":"CXCL12 (SDF-1/PBSF) is a constitutively secreted chemokine that orchestrates cell migration, survival, and tissue development, established by germline knockout mice that die perinatally with defective B-cell lymphopoiesis, bone-marrow myelopoiesis, and cardiac ventricular septation [PMID:8757135]. Its signaling output is determined by two receptors: the G-protein-coupled receptor CXCR4 transduces directional and proliferative signals, while the atypical receptor CXCR7/ACKR3 shapes ligand availability—it constitutively internalizes and degrades CXCL12 without ligand saturation [PMID:20161793], regulates circulating plasma CXCL12 levels through venular endothelium [PMID:24116850], and heterodimerizes with CXCR4 to impair Gαi activation and calcium responses, dampening chemotaxis [PMID:19380869]. Through CXCR4, CXCL12 engages context-dependent intracellular cascades that converge on cytoskeletal and survival machinery: a PAK1/2→p38α→MAPKAP-K2→HSP27 axis required for migration [PMID:16574378], Rac1/PAK-driven actin polymerization controlling dendritic spine plasticity [PMID:31971513], ABL2(Arg)-mediated cortactin Y421 phosphorylation driving invadopodia and invasion [PMID:32035133], PI3K/AKT/mTOR signaling promoting neurite regeneration and mTORC2-dependent angiogenesis [PMID:23578489, PMID:27106789], ERK1/2 supporting cancer-stem-cell invasion and lymphangiogenesis [PMID:28193907, PMID:22932666], JAK/Gi-dependent immunological synapse formation in T cells [PMID:25917087], and Btk-driven integrin αIIbβ3 activation underlying platelet aggregation and arterial thrombosis [PMID:35313337]. CXCL12 activity is further tuned by structural and transcriptional regulation: distinct, non-overlapping receptor-binding and glycosaminoglycan-binding surfaces allow GAGs to anchor haptotactic gradients in tissue while leaving the receptor epitope free [PMID:18334249], an Asn44/Asn45–RFFESH 'hot spot' governs binding to both CXCR4 and CXCR7 [PMID:23812669], promoter DNA methylation and STAT3-p300-driven histone acetylation control its expression [PMID:21753787, PMID:28072604], and it can form a chemotactic heterocomplex with reduced HMGB1 that signals through CXCR4 [PMID:31418171]. In disease contexts these mechanisms drive rheumatoid synovial MMP expression [PMID:21753787], atherosclerotic suppression of macrophage cholesterol efflux [PMID:31662443], chemotherapy-induced nociception [PMID:28072604], and senescent-fibroblast-mediated tumor immunosuppression [PMID:39251867].","teleology":[{"year":1996,"claim":"Established that CXCL12 is non-redundantly required for development, defining its core physiological roles before its receptors and signaling were dissected.","evidence":"Germline knockout mouse with histological and progenitor analyses","pmids":["8757135"],"confidence":"High","gaps":["Did not identify the receptor mediating each phenotype","Cell-autonomous versus niche contributions not resolved","Downstream signaling cascades undefined"]},{"year":2008,"claim":"Resolved how CXCL12 is positioned in tissue versus how it engages its receptor, showing receptor-binding and glycosaminoglycan-binding surfaces are structurally separable.","evidence":"NMR epitope mapping and isoform-specific GAG-binding assays","pmids":["18334249"],"confidence":"Medium","gaps":["In vivo contribution of GAG anchoring to gradient formation not directly tested here","Functional consequence of isoform-specific GAG affinity differences incomplete"]},{"year":2006,"claim":"Defined a discrete kinase cascade linking CXCL12 stimulation to the actin/migration machinery, moving beyond Gαi/calcium readouts.","evidence":"p38α knockout mice, RNAi of MAPKAP-K2/HSP27, and pharmacological inhibition in migration assays","pmids":["16574378"],"confidence":"High","gaps":["Receptor (CXCR4 vs CXCR7) upstream of PAK not specified","Direct HSP27 effector targets on the cytoskeleton not mapped"]},{"year":2009,"claim":"Explained how CXCR7 modulates CXCR4 output, demonstrating constitutive heterodimerization that conformationally suppresses Gαi activation and chemotaxis.","evidence":"BRET/FRET, calcium flux, and chemotaxis assays in T cells and transfected lines","pmids":["19380869"],"confidence":"High","gaps":["Stoichiometry of heterodimers in native cells unclear","In vivo relevance of dimer-mediated dampening not established here"]},{"year":2010,"claim":"Reframed CXCR7 as a scavenger that controls CXCL12 abundance, distinguishing ligand availability regulation from classical signaling.","evidence":"Internalization, degradation, and cycling assays across cell lines, mouse tissue, and zebrafish","pmids":["20161793"],"confidence":"High","gaps":["Trafficking adaptors mediating CXCR7 cycling not identified","Quantitative impact on tissue gradients not measured"]},{"year":2011,"claim":"Demonstrated promoter DNA hypomethylation as a transcriptional driver of pathological CXCL12 expression and assigned a CXCR7-dependent downstream effect.","evidence":"Bisulfite sequencing, demethylation treatment, and receptor-specific siRNA in rheumatoid synovial fibroblasts","pmids":["21753787"],"confidence":"Medium","gaps":["Methyltransferase/demethylase responsible not identified","CXCR7-to-MMP signaling intermediates undefined"]},{"year":2011,"claim":"Established the molecular basis of CXCL12 paralog/receptor selectivity, showing a single residue tunes affinity to direct germ cell migration.","evidence":"Zebrafish genetics, site-directed mutagenesis, and PGC migration/affinity assays","pmids":["21693511"],"confidence":"Medium","gaps":["Generalizability of the affinity rule to mammalian isoforms not tested","Structural basis of the affinity shift not resolved"]},{"year":2013,"claim":"Identified the shared CXCL12 surface engaging both receptors, locating Asn44/Asn45 and RFFESH as the binding hot spot.","evidence":"X-ray crystallography of a Fab/CXCL12α complex with mutagenesis and binding/migration assays","pmids":["23812669"],"confidence":"High","gaps":["Does not explain receptor selectivity since the site is shared","Conformational differences between CXCR4 and CXCR7 engagement unresolved"]},{"year":2013,"claim":"Linked CXCL12/CXCR4 to neuronal regeneration through a specific PI3K/AKT/mTOR route, excluding JAK/STAT3.","evidence":"RGC neurite assays on myelin, receptor and pathway inhibitors, and an in vivo optic nerve crush model","pmids":["23578489"],"confidence":"Medium","gaps":["mTOR complex specificity not distinguished here","Disinhibition mechanism toward myelin not molecularly defined"]},{"year":2015,"claim":"Showed CXCL12/CXCR4 shapes the T cell immunological synapse via Gi/JAK-dependent actin and MTOC organization, connecting the chemokine to adaptive immune activation.","evidence":"CXCR4 siRNA/blockade, confocal imaging, flow cytometry, and JAK inhibition in T cells","pmids":["25917087"],"confidence":"Medium","gaps":["Direct JAK substrates at the synapse not identified","Physiological in vivo consequence for T cell responses not tested"]},{"year":2015,"claim":"Connected CXCL12/CXCR4 signaling to a tetraspanin (CD9) program promoting myoblast migration and fusion in muscle regeneration.","evidence":"Muscle injury models, receptor-specific siRNA, and migration/fusion assays across stem cell types","pmids":["25890097"],"confidence":"Medium","gaps":["Signaling steps linking CXCR4 to CD9 transcription unmapped","Whether CD9 is necessary for the in vivo regenerative phenotype unclear"]},{"year":2016,"claim":"Defined the mTOR complex specificity of CXCL12-driven angiogenesis, showing mTORC2/PFKFB3 glycolytic control of sprouting.","evidence":"Complex-specific siRNA, pharmacology, Akt-Ser473 readout, and 3D/in vivo angiogenesis models","pmids":["27106789"],"confidence":"Medium","gaps":["Link between mTORC2 and PFKFB3 induction not mechanistically detailed","Endothelial versus tumor cell source of signal not separated"]},{"year":2016,"claim":"Showed oncogenic JAK2 amplifies CXCL12/CXCR4 chemotaxis via PI3K, providing a disease context for enhanced responsiveness in myeloproliferative neoplasms.","evidence":"MPL-W515L expression, JAK2 knockdown/inhibition, and chemotaxis of patient CD34+ cells","pmids":["28903325"],"confidence":"Medium","gaps":["Direct biochemical interaction between JAK2 and CXCR4 signaling not demonstrated","Receptor-level mechanism of sensitization unresolved"]},{"year":2017,"claim":"Uncovered transcriptional induction of CXCL12 by chemotherapy through STAT3-p300 histone acetylation, linking it to neuropathic pain via CXCR4-potentiated synaptic transmission.","evidence":"CoIP, ChIP, STAT3 genetics/inhibition, CXCL12 knockout, and electrophysiology in spinal neurons","pmids":["28072604"],"confidence":"High","gaps":["CXCR4 downstream effectors potentiating mEPSCs not detailed","Generalizability beyond antitubulin agents untested"]},{"year":2017,"claim":"Established autocrine CXCL12/CXCR4/ERK1/2 signaling as a driver of cancer-stem-cell invasion and metastasis.","evidence":"Loss- and gain-of-function with ERK readout in vitro and in vivo metastasis model","pmids":["28193907"],"confidence":"Medium","gaps":["ERK downstream invasion effectors not identified","Contribution of CXCR7 not assessed"]},{"year":2019,"claim":"Defined a platelet-intrinsic CXCL12/CXCR4/Btk→integrin αIIbβ3 cascade controlling thrombosis without affecting hemostasis.","evidence":"Platelet-specific CXCL12 knockout, Btk phosphorylation, aggregation under flow, and carotid injury model","pmids":["35313337"],"confidence":"High","gaps":["Source of CXCL12 acting in trans versus cis not fully resolved","Coupling between Btk and integrin inside-out signaling not detailed"]},{"year":2019,"claim":"Showed CXCL12/CXCR4 suppresses macrophage cholesterol efflux through a GSK3β/β-catenin/TCF21→ABCA1 transcriptional axis, implicating it in atherosclerosis.","evidence":"Luciferase, ChIP, phospho-immunoblotting, receptor knockdown, and Apoe-/- in vivo overexpression","pmids":["31662443"],"confidence":"Medium","gaps":["Direct CXCR4-to-GSK3β coupling mechanism not shown","Relative contribution to plaque burden quantitatively limited"]},{"year":2019,"claim":"Demonstrated CXCL12 forms a functional heterocomplex with reduced HMGB1 that enhances CXCR4-dependent inflammatory recruitment, defining a druggable composite chemoattractant.","evidence":"NMR binding, chemotaxis, and in vivo recruitment with diflunisal disruption","pmids":["31418171"],"confidence":"High","gaps":["Structural basis of heterocomplex-CXCR4 engagement not resolved","Endogenous regulation of the complex in vivo unclear"]},{"year":2020,"claim":"Linked CXCL12/CXCR4 to synaptic plasticity via Rac1/PAK actin polymerization, showing it restores dendritic spines and cognitive flexibility.","evidence":"Neuroinflammation model, intracranial CXCL12, CXCR4 antagonism, pathway inhibition, and spine imaging","pmids":["31971513"],"confidence":"Medium","gaps":["Molecular link from CXCR4 to Rac1 activation not detailed","Specificity for thin spines mechanistically unexplained"]},{"year":2020,"claim":"Identified ABL2(Arg)-mediated cortactin Y421 phosphorylation as the mechanism for CXCL12/CXCR4-driven invadopodia formation in glioma.","evidence":"Arg siRNA, cortactin phosphorylation, CoIP, and invadopodia/invasion assays","pmids":["32035133"],"confidence":"Medium","gaps":["How CXCR4 activates Arg kinase not defined","In vivo invasion contribution not tested here"]},{"year":2024,"claim":"Connected senescent-fibroblast-derived CXCL12 to tumor immunosuppression, showing it blocks CD8 T cell differentiation and recruits MDSCs.","evidence":"p16-reporter mice, scRNA-seq, senescent-cell elimination, CXCL12 inhibition, and bispecific anti-CXCL12/PD1 antibody","pmids":["39251867"],"confidence":"Medium","gaps":["Receptor (CXCR4 vs CXCR7) on T cells/MDSCs not specified","Direct signaling pathway in target immune cells undefined"]},{"year":null,"claim":"How the shared Asn44/Asn45-RFFESH binding hot spot produces distinct signaling versus scavenging outcomes at CXCR4 versus CXCR7, and how post-translational modifications and GAG anchoring quantitatively shape gradients in vivo, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model distinguishing CXCR4 versus CXCR7 engagement of the shared epitope","Quantitative in vivo contribution of GAG binding and proteolytic/citrullination modifications to gradient formation not established","Receptor identity unassigned in several disease contexts"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[1,8,13,18]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,3,11,12]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[22]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,6,13]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[22]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,3,7,11,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,12,21]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,18,20]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[11]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[1,2]}],"complexes":["CXCL12–CXCR4 (heterodimer with CXCR7/ACKR3)","CXCL12–HMGB1 heterocomplex"],"partners":["CXCR4","CXCR7/ACKR3","HMGB1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P48061","full_name":"Stromal cell-derived factor 1","aliases":["C-X-C motif chemokine 12","Intercrine reduced in hepatomas","IRH","hIRH","Pre-B cell growth-stimulating factor","PBSF"],"length_aa":93,"mass_kda":10.7,"function":"Chemoattractant active on T-lymphocytes and monocytes but not neutrophils (PubMed:18802065, PubMed:39093700). Activates the C-X-C chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis (PubMed:8752281, PubMed:18802065, PubMed:39093700). Also binds to atypical chemokine receptor ACKR3, which activates the beta-arrestin pathway and acts as a scavenger receptor for CXCL12/SDF-1 (PubMed:16107333, PubMed:19255243). Binds to the allosteric site (site 2) of integrins and activates integrins ITGAV:ITGB3, ITGA4:ITGB1 and ITGA5:ITGB1 in a CXCR4-independent manner (PubMed:29301984). Acts as a positive regulator of monocyte migration and a negative regulator of monocyte adhesion via the LYN kinase (PubMed:18802065). Stimulates migration of monocytes and T-lymphocytes through its receptors, CXCR4 and ACKR3, and decreases monocyte adherence to surfaces coated with ICAM-1, a ligand for beta-2 integrins (PubMed:16107333, PubMed:18802065, PubMed:19255243, PubMed:39093700). CXCR4 signaling axis inhibits beta-2 integrin LFA-1 mediated adhesion of monocytes to ICAM-1 through LYN kinase (PubMed:18802065). Inhibits CXCR4-mediated infection by T-cell line-adapted HIV-1 (PubMed:8752281). Plays a protective role after myocardial infarction. Induces down-regulation and internalization of ACKR3 expressed in various cells. Has several critical functions during embryonic development; required for B-cell lymphopoiesis, myelopoiesis in bone marrow and heart ventricular septum formation (By similarity). Stimulates the proliferation of bone marrow-derived B-cell progenitors in the presence of IL7 as well as growth of stromal cell-dependent pre-B-cells (By similarity) Shows a reduced chemotactic activity Shows a reduced chemotactic activity (PubMed:14525775). Binding to cell surface proteoglycans seems to inhibit formation of SDF-1-alpha(3-67) and thus to preserve activity on local sites (PubMed:14525775)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P48061/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CXCL12","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CXCL12","total_profiled":1310},"omim":[{"mim_id":"619215","title":"OCULOMOTOR-ABDUCENS SYNKINESIS; OCABSN","url":"https://www.omim.org/entry/619215"},{"mim_id":"618806","title":"T-CELL LYMPHOPENIA, INFANTILE, WITH OR WITHOUT NAIL DYSTROPHY, AUTOSOMAL DOMINANT; TLIND","url":"https://www.omim.org/entry/618806"},{"mim_id":"618534","title":"IMMUNODEFICIENCY 64 WITH LYMPHOPROLIFERATION; IMD64","url":"https://www.omim.org/entry/618534"},{"mim_id":"617424","title":"WD REPEAT-CONTAINING PROTEIN 26; WDR26","url":"https://www.omim.org/entry/617424"},{"mim_id":"614596","title":"MICRO RNA 302A; MIR302A","url":"https://www.omim.org/entry/614596"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CXCL12"},"hgnc":{"alias_symbol":["SCYB12","SDF-1a","SDF-1b","PBSF","TLSF-a","TLSF-b","TPAR1"],"prev_symbol":["SDF1A","SDF1B","SDF1"]},"alphafold":{"accession":"P48061","domains":[{"cath_id":"2.40.50.40","chopping":"33-93","consensus_level":"medium","plddt":88.1885,"start":33,"end":93}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P48061","model_url":"https://alphafold.ebi.ac.uk/files/AF-P48061-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P48061-F1-predicted_aligned_error_v6.png","plddt_mean":83.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CXCL12","jax_strain_url":"https://www.jax.org/strain/search?query=CXCL12"},"sequence":{"accession":"P48061","fasta_url":"https://rest.uniprot.org/uniprotkb/P48061.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P48061/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P48061"}},"corpus_meta":[{"pmid":"8757135","id":"PMC_8757135","title":"Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8757135","citation_count":1875,"is_preprint":false},{"pmid":"20484021","id":"PMC_20484021","title":"CXCL12 (SDF-1)/CXCR4 pathway in cancer.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/20484021","citation_count":1211,"is_preprint":false},{"pmid":"20839032","id":"PMC_20839032","title":"CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.","date":"2010","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20839032","citation_count":608,"is_preprint":false},{"pmid":"22683307","id":"PMC_22683307","title":"A review on CXCR4/CXCL12 axis in oncology: no place to hide.","date":"2012","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/22683307","citation_count":532,"is_preprint":false},{"pmid":"19380869","id":"PMC_19380869","title":"CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19380869","citation_count":507,"is_preprint":false},{"pmid":"20161793","id":"PMC_20161793","title":"CXCR7 functions as a scavenger for CXCL12 and CXCL11.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20161793","citation_count":391,"is_preprint":false},{"pmid":"21349998","id":"PMC_21349998","title":"CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21349998","citation_count":343,"is_preprint":false},{"pmid":"29082918","id":"PMC_29082918","title":"The unique structural and functional features of CXCL12.","date":"2017","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29082918","citation_count":306,"is_preprint":false},{"pmid":"20930067","id":"PMC_20930067","title":"The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20930067","citation_count":260,"is_preprint":false},{"pmid":"33363463","id":"PMC_33363463","title":"The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33363463","citation_count":243,"is_preprint":false},{"pmid":"16046252","id":"PMC_16046252","title":"Functions of CXCL12 and CXCR4 in breast cancer.","date":"2005","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/16046252","citation_count":235,"is_preprint":false},{"pmid":"11953881","id":"PMC_11953881","title":"CXCR4/CXCL12 expression and signalling in kidney cancer.","date":"2002","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11953881","citation_count":214,"is_preprint":false},{"pmid":"28875842","id":"PMC_28875842","title":"Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.","date":"2019","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28875842","citation_count":208,"is_preprint":false},{"pmid":"18533280","id":"PMC_18533280","title":"CXCR7, CXCR4 and CXCL12: an eccentric trio?","date":"2008","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/18533280","citation_count":199,"is_preprint":false},{"pmid":"9653044","id":"PMC_9653044","title":"A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection.","date":"1998","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9653044","citation_count":191,"is_preprint":false},{"pmid":"37497001","id":"PMC_37497001","title":"CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37497001","citation_count":175,"is_preprint":false},{"pmid":"23153575","id":"PMC_23153575","title":"CXCR7 impact on CXCL12 biology and disease.","date":"2012","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23153575","citation_count":175,"is_preprint":false},{"pmid":"21158728","id":"PMC_21158728","title":"CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization.","date":"2010","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/21158728","citation_count":173,"is_preprint":false},{"pmid":"22989616","id":"PMC_22989616","title":"Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.","date":"2012","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22989616","citation_count":165,"is_preprint":false},{"pmid":"30396776","id":"PMC_30396776","title":"Pathological roles of the homeostatic chemokine CXCL12.","date":"2018","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/30396776","citation_count":153,"is_preprint":false},{"pmid":"24722947","id":"PMC_24722947","title":"CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4.","date":"2014","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/24722947","citation_count":138,"is_preprint":false},{"pmid":"31507535","id":"PMC_31507535","title":"The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases.","date":"2019","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31507535","citation_count":136,"is_preprint":false},{"pmid":"29017963","id":"PMC_29017963","title":"The role of CXCL12 in tumor microenvironment.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/29017963","citation_count":124,"is_preprint":false},{"pmid":"16574378","id":"PMC_16574378","title":"CXCL12 and C5a trigger cell migration via a PAK1/2-p38alpha MAPK-MAPKAP-K2-HSP27 pathway.","date":"2006","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/16574378","citation_count":103,"is_preprint":false},{"pmid":"22932666","id":"PMC_22932666","title":"The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis.","date":"2012","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/22932666","citation_count":101,"is_preprint":false},{"pmid":"19774645","id":"PMC_19774645","title":"CXCL12 is a constitutive and inflammatory chemokine in the intestinal immune system.","date":"2010","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/19774645","citation_count":101,"is_preprint":false},{"pmid":"19258077","id":"PMC_19258077","title":"CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival.","date":"2008","source":"The Journal of thoracic and cardiovascular surgery","url":"https://pubmed.ncbi.nlm.nih.gov/19258077","citation_count":100,"is_preprint":false},{"pmid":"35565443","id":"PMC_35565443","title":"CXCR4/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35565443","citation_count":99,"is_preprint":false},{"pmid":"23382785","id":"PMC_23382785","title":"Involvement of CXCR4/CXCR7/CXCL12 Interactions in Inflammatory bowel disease.","date":"2013","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/23382785","citation_count":98,"is_preprint":false},{"pmid":"22204316","id":"PMC_22204316","title":"Roles of chemokine CXCL12 and its receptors in ischemic stroke.","date":"2012","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/22204316","citation_count":94,"is_preprint":false},{"pmid":"18644448","id":"PMC_18644448","title":"CXCL12/CXCR4 signalling in neuronal cell migration.","date":"2008","source":"Current opinion in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/18644448","citation_count":93,"is_preprint":false},{"pmid":"21082982","id":"PMC_21082982","title":"CXCL12 and CXCR4 in bone marrow physiology.","date":"2010","source":"Expert review of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/21082982","citation_count":93,"is_preprint":false},{"pmid":"21753787","id":"PMC_21753787","title":"DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts.","date":"2011","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/21753787","citation_count":92,"is_preprint":false},{"pmid":"24024928","id":"PMC_24024928","title":"Platelet-derived CXCL12 (SDF-1α): basic mechanisms and clinical implications.","date":"2013","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/24024928","citation_count":91,"is_preprint":false},{"pmid":"23279723","id":"PMC_23279723","title":"An infernal trio: the chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology.","date":"2012","source":"Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft","url":"https://pubmed.ncbi.nlm.nih.gov/23279723","citation_count":87,"is_preprint":false},{"pmid":"11197205","id":"PMC_11197205","title":"A chemokine, SDF-1/PBSF, and its receptor, CXC chemokine receptor 4, as mediators of hematopoiesis.","date":"2000","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/11197205","citation_count":83,"is_preprint":false},{"pmid":"25075251","id":"PMC_25075251","title":"Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis.","date":"2014","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/25075251","citation_count":82,"is_preprint":false},{"pmid":"29903571","id":"PMC_29903571","title":"Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.","date":"2018","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/29903571","citation_count":81,"is_preprint":false},{"pmid":"36442720","id":"PMC_36442720","title":"CXCL12/CXCR4: An amazing challenge and opportunity in the fight against fibrosis.","date":"2022","source":"Ageing research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/36442720","citation_count":79,"is_preprint":false},{"pmid":"24116850","id":"PMC_24116850","title":"Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels.","date":"2014","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24116850","citation_count":77,"is_preprint":false},{"pmid":"19625779","id":"PMC_19625779","title":"CXCL12, CXCR4 and CXCR7 expression in brain metastases.","date":"2009","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19625779","citation_count":72,"is_preprint":false},{"pmid":"33096815","id":"PMC_33096815","title":"The Signaling Duo CXCL12 and CXCR4: Chemokine Fuel for Breast Cancer Tumorigenesis.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33096815","citation_count":69,"is_preprint":false},{"pmid":"28072604","id":"PMC_28072604","title":"Epigenetic upregulation of CXCL12 expression mediates antitubulin chemotherapeutics-induced neuropathic pain.","date":"2017","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/28072604","citation_count":63,"is_preprint":false},{"pmid":"9657103","id":"PMC_9657103","title":"Interleukin-8 and hIRH (SDF1-alpha/PBSF) mRNA expression and histological activity index in patients with chronic hepatitis C.","date":"1998","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/9657103","citation_count":59,"is_preprint":false},{"pmid":"26353174","id":"PMC_26353174","title":"CXCL12/CXCR4 axis: an emerging neuromodulator in pathological pain.","date":"2016","source":"Reviews in the neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/26353174","citation_count":59,"is_preprint":false},{"pmid":"29398278","id":"PMC_29398278","title":"Multisystem multitasking by CXCL12 and its receptors CXCR4 and ACKR3.","date":"2018","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/29398278","citation_count":58,"is_preprint":false},{"pmid":"19670960","id":"PMC_19670960","title":"Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus.","date":"2009","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/19670960","citation_count":57,"is_preprint":false},{"pmid":"18334249","id":"PMC_18334249","title":"Relationships between glycosaminoglycan and receptor binding sites in chemokines-the CXCL12 example.","date":"2008","source":"Carbohydrate research","url":"https://pubmed.ncbi.nlm.nih.gov/18334249","citation_count":57,"is_preprint":false},{"pmid":"22270883","id":"PMC_22270883","title":"CXCL12 signaling in the development of the nervous system.","date":"2012","source":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22270883","citation_count":56,"is_preprint":false},{"pmid":"16045736","id":"PMC_16045736","title":"CXCL12 and CXCR4 expression by human gingival fibroblasts in periodontal disease.","date":"2005","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16045736","citation_count":56,"is_preprint":false},{"pmid":"27106789","id":"PMC_27106789","title":"mTORC2 mediates CXCL12-induced angiogenesis.","date":"2016","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/27106789","citation_count":55,"is_preprint":false},{"pmid":"34286441","id":"PMC_34286441","title":"CXCL12 Signaling in the Tumor Microenvironment.","date":"2021","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/34286441","citation_count":54,"is_preprint":false},{"pmid":"31336263","id":"PMC_31336263","title":"Stromal cell-derived factor-1 (CXCL12) and its role in bone and muscle biology.","date":"2019","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/31336263","citation_count":54,"is_preprint":false},{"pmid":"28132854","id":"PMC_28132854","title":"Misbalanced CXCL12 and CCL5 Chemotactic Signals in Vitiligo Onset and Progression.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28132854","citation_count":54,"is_preprint":false},{"pmid":"31662443","id":"PMC_31662443","title":"CXCL12 promotes atherosclerosis by downregulating ABCA1 expression via the CXCR4/GSK3β/β-cateninT120/TCF21 pathway.","date":"2019","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/31662443","citation_count":52,"is_preprint":false},{"pmid":"19594447","id":"PMC_19594447","title":"Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7.","date":"2009","source":"BioTechniques","url":"https://pubmed.ncbi.nlm.nih.gov/19594447","citation_count":52,"is_preprint":false},{"pmid":"26257740","id":"PMC_26257740","title":"MIF and CXCL12 in Cardiovascular Diseases: Functional Differences and Similarities.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26257740","citation_count":50,"is_preprint":false},{"pmid":"33530455","id":"PMC_33530455","title":"The CXCL12 Crossroads in Cancer Stem Cells and Their Niche.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33530455","citation_count":49,"is_preprint":false},{"pmid":"27082011","id":"PMC_27082011","title":"Expression and function of CXCL12/CXCR4/CXCR7 in thyroid cancer.","date":"2016","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27082011","citation_count":49,"is_preprint":false},{"pmid":"39393439","id":"PMC_39393439","title":"CXCL12+ tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma.","date":"2024","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/39393439","citation_count":47,"is_preprint":false},{"pmid":"28193907","id":"PMC_28193907","title":"Stem cell autocrine CXCL12/CXCR4 stimulates invasion and metastasis of esophageal cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28193907","citation_count":47,"is_preprint":false},{"pmid":"23578489","id":"PMC_23578489","title":"CXCL12/SDF-1 facilitates optic nerve regeneration.","date":"2013","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/23578489","citation_count":46,"is_preprint":false},{"pmid":"29304539","id":"PMC_29304539","title":"Expression and Cellular Localization of CXCR4 and CXCL12 in Human Carotid Atherosclerotic Plaques.","date":"2018","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/29304539","citation_count":45,"is_preprint":false},{"pmid":"21084856","id":"PMC_21084856","title":"Expression of the new CXCL12 receptor, CXCR7, in gliomas.","date":"2011","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21084856","citation_count":42,"is_preprint":false},{"pmid":"17320408","id":"PMC_17320408","title":"The role of the chemokine CXCL12 in osteoclastogenesis.","date":"2007","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/17320408","citation_count":42,"is_preprint":false},{"pmid":"26369824","id":"PMC_26369824","title":"Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.","date":"2016","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26369824","citation_count":39,"is_preprint":false},{"pmid":"25372750","id":"PMC_25372750","title":"CXCL14 antagonizes the CXCL12-CXCR4 signaling axis.","date":"2014","source":"Biomolecular concepts","url":"https://pubmed.ncbi.nlm.nih.gov/25372750","citation_count":39,"is_preprint":false},{"pmid":"37949685","id":"PMC_37949685","title":"An emerging paradigm of CXCL12 involvement in the metastatic cascade.","date":"2023","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/37949685","citation_count":38,"is_preprint":false},{"pmid":"35406582","id":"PMC_35406582","title":"Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35406582","citation_count":38,"is_preprint":false},{"pmid":"31275385","id":"PMC_31275385","title":"CXCL12 and Its Isoforms: Different Roles in Pancreatic Cancer?","date":"2019","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31275385","citation_count":38,"is_preprint":false},{"pmid":"23382781","id":"PMC_23382781","title":"The role of CXCL12-CXCR4 signaling pathway in pancreatic development.","date":"2013","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/23382781","citation_count":36,"is_preprint":false},{"pmid":"23812669","id":"PMC_23812669","title":"Development and preclinical characterization of a humanized antibody targeting CXCL12.","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23812669","citation_count":36,"is_preprint":false},{"pmid":"31145896","id":"PMC_31145896","title":"CXC chemokine ligand 12 (CXCL12) in atherosclerosis: An underlying therapeutic target.","date":"2019","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31145896","citation_count":36,"is_preprint":false},{"pmid":"21294125","id":"PMC_21294125","title":"The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.","date":"2011","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21294125","citation_count":36,"is_preprint":false},{"pmid":"31418171","id":"PMC_31418171","title":"Diflunisal targets the HMGB1/CXCL12 heterocomplex and blocks immune cell recruitment.","date":"2019","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/31418171","citation_count":35,"is_preprint":false},{"pmid":"31971513","id":"PMC_31971513","title":"CXCL12-induced rescue of cortical dendritic spines and cognitive flexibility.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31971513","citation_count":33,"is_preprint":false},{"pmid":"35313337","id":"PMC_35313337","title":"Targeting platelet-derived CXCL12 impedes arterial thrombosis.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/35313337","citation_count":32,"is_preprint":false},{"pmid":"25890097","id":"PMC_25890097","title":"Sdf-1 (CXCL12) induces CD9 expression in stem cells engaged in muscle regeneration.","date":"2015","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25890097","citation_count":32,"is_preprint":false},{"pmid":"22173290","id":"PMC_22173290","title":"Strong expression of CXCL12 is associated with a favorable outcome in osteosarcoma.","date":"2011","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/22173290","citation_count":32,"is_preprint":false},{"pmid":"32801831","id":"PMC_32801831","title":"NLRP3 Regulated CXCL12 Expression in Acute Neutrophilic Lung Injury.","date":"2020","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/32801831","citation_count":31,"is_preprint":false},{"pmid":"35772647","id":"PMC_35772647","title":"Zedoarondiol inhibits atherosclerosis by regulating monocyte migration and adhesion via CXCL12/CXCR4 pathway.","date":"2022","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/35772647","citation_count":30,"is_preprint":false},{"pmid":"34117709","id":"PMC_34117709","title":"miR-126-3p is essential for CXCL12-induced angiogenesis.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34117709","citation_count":30,"is_preprint":false},{"pmid":"28903325","id":"PMC_28903325","title":"CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28903325","citation_count":30,"is_preprint":false},{"pmid":"32485053","id":"PMC_32485053","title":"CXCL12 in normal and pathological pregnancies: A review.","date":"2020","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/32485053","citation_count":29,"is_preprint":false},{"pmid":"22172378","id":"PMC_22172378","title":"SDF-1/CXCL12: its role in spinal cord injury.","date":"2011","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22172378","citation_count":29,"is_preprint":false},{"pmid":"25484899","id":"PMC_25484899","title":"Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System.","date":"2014","source":"International journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25484899","citation_count":29,"is_preprint":false},{"pmid":"25917087","id":"PMC_25917087","title":"CXCL12 Regulates through JAK1 and JAK2 Formation of Productive Immunological Synapses.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25917087","citation_count":29,"is_preprint":false},{"pmid":"22392052","id":"PMC_22392052","title":"CXCL12 in control of neuroinflammation.","date":"2012","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/22392052","citation_count":28,"is_preprint":false},{"pmid":"33973098","id":"PMC_33973098","title":"The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers.","date":"2021","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/33973098","citation_count":28,"is_preprint":false},{"pmid":"24808825","id":"PMC_24808825","title":"CXCL12 chemokine and GABA neurotransmitter systems crosstalk and their putative roles.","date":"2014","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24808825","citation_count":27,"is_preprint":false},{"pmid":"24879309","id":"PMC_24879309","title":"The CXCR4/CXCL12 axis in cutaneous malignancies with an emphasis on melanoma.","date":"2014","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/24879309","citation_count":27,"is_preprint":false},{"pmid":"21693511","id":"PMC_21693511","title":"Cxcl12 evolution--subfunctionalization of a ligand through altered interaction with the chemokine receptor.","date":"2011","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21693511","citation_count":27,"is_preprint":false},{"pmid":"39251867","id":"PMC_39251867","title":"Preexisting senescent fibroblasts in the aged bladder create a tumor-permissive niche through CXCL12 secretion.","date":"2024","source":"Nature aging","url":"https://pubmed.ncbi.nlm.nih.gov/39251867","citation_count":26,"is_preprint":false},{"pmid":"25400097","id":"PMC_25400097","title":"Role of CXCL12 and CXCR4 in normal cerebellar development and medulloblastoma.","date":"2014","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25400097","citation_count":26,"is_preprint":false},{"pmid":"38920657","id":"PMC_38920657","title":"Crosstalk between CXCL12/CXCR4/ACKR3 and the STAT3 Pathway.","date":"2024","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/38920657","citation_count":25,"is_preprint":false},{"pmid":"11795258","id":"PMC_11795258","title":"Role of chemokine SDF-1/PBSF and its receptor CXCR4 in blood vessel development.","date":"2001","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11795258","citation_count":24,"is_preprint":false},{"pmid":"34179113","id":"PMC_34179113","title":"The Role of CXCL12 in Kidney Diseases: A Friend or Foe?","date":"2021","source":"Kidney diseases (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34179113","citation_count":24,"is_preprint":false},{"pmid":"32883765","id":"PMC_32883765","title":"Functions of the CXCL12 Receptor ACKR3/CXCR7-What Has Been Perceived and What Has Been Overlooked.","date":"2020","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32883765","citation_count":24,"is_preprint":false},{"pmid":"32035133","id":"PMC_32035133","title":"Arg kinase mediates CXCL12/CXCR4-induced invadopodia formation and invasion of glioma cells.","date":"2020","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/32035133","citation_count":23,"is_preprint":false},{"pmid":"10200343","id":"PMC_10200343","title":"Reduced expression of the CXCR4 receptor mRNA in hepatocellular carcinoma and lack of inducibility of its ligand alpha-chemokine hIRH/SDF1alpha/PBSF in vitro.","date":"1999","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/10200343","citation_count":23,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48467,"output_tokens":6539,"usd":0.121743,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15181,"output_tokens":6226,"usd":0.115778,"stage2_stop_reason":"end_turn"},"total_usd":0.237521,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"Targeted disruption of PBSF/SDF-1 (CXCL12) in mice resulted in perinatal lethality with severe reduction of B-cell progenitors in fetal liver and bone marrow, reduction of myeloid progenitors specifically in bone marrow but not fetal liver, and cardiac ventricular septal defect, establishing CXCL12 as essential for B-cell lymphopoiesis, bone-marrow myelopoiesis, and cardiogenesis.\",\n      \"method\": \"Targeted gene disruption (knockout mouse), histological and progenitor cell analyses\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean germline knockout with defined developmental phenotypes, replicated across multiple organ systems in a single rigorous study; foundational paper widely confirmed\",\n      \"pmids\": [\"8757135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCR7 constitutively heterodimerizes with CXCR4 as efficiently as homodimerization; CXCR7 expression induces conformational rearrangements within preassembled CXCR4/Gαi complexes and impairs CXCR4-promoted Gαi-protein activation and calcium responses to CXCL12, thereby modulating CXCL12-mediated chemotaxis in T cells.\",\n      \"method\": \"BRET/FRET energy transfer assays, calcium flux assays, chemotaxis assays in primary T cells and transfected cell lines, CXCL12/CXCR7 blocking experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (energy transfer, calcium flux, chemotaxis) in a single lab; mechanistic pathway established\",\n      \"pmids\": [\"19380869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CXCR7 acts as a specific scavenger receptor for CXCL12 (and CXCL11), mediating constitutive ligand internalization and targeting chemokine cargo for degradation; CXCR7 continuously cycles between the plasma membrane and intracellular compartments independently of ligand, and CXCR7-dependent chemokine degradation is not saturated with increasing ligand concentrations.\",\n      \"method\": \"Ligand internalization assays, degradation assays in mammalian cells and zebrafish, live cell imaging, in situ studies in mouse heart valves and human umbilical vein endothelium\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (internalization, degradation, cycling, in vivo validation) across cell lines, primary tissue, and two species\",\n      \"pmids\": [\"20161793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CXCL12-induced cell migration requires a PAK1/2 → p38α MAPK → MAPKAP-K2 → HSP27 signaling pathway; pharmacological inhibition or genetic ablation of p38α, RNAi against MAPKAP-K2, or RNAi against HSP27 each blocked CXCL12-induced cell migration.\",\n      \"method\": \"Pharmacological inhibition (SB203580, BIRB0796), genetic p38α knockout mice, RNA interference (MAPKAP-K2, HSP27), macrophage migration assay, HeLa cell migration assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal genetic and pharmacological interventions across cell types and mouse models converge on the same pathway\",\n      \"pmids\": [\"16574378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"DNA hypomethylation of the CXCL12 promoter in rheumatoid arthritis synovial fibroblasts (RASFs) drives increased CXCL12 expression relative to osteoarthritis SFs; CXCL12 stimulation of RASFs increases MMP expression via CXCR7 (not CXCR4), as demonstrated by CXCR7 siRNA knockdown.\",\n      \"method\": \"Bisulfite sequencing, McrBC methylation assay, 5-azacytidine demethylation, ELISA, CXCR7 siRNA transfection, real-time PCR for MMPs\",\n      \"journal\": \"Genes and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (methylation analysis, demethylation treatment, receptor-specific siRNA) in a single lab\",\n      \"pmids\": [\"21753787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CXCL12 promotes lymphangiogenesis and lymphatic endothelial cell (LEC) migration and tube formation via CXCR4, activating intracellular Akt and Erk phosphorylation; the CXCL12-CXCR4 axis promotes lymphangiogenesis independently of the VEGFR-3 pathway in vivo.\",\n      \"method\": \"In vitro LEC migration and tubule formation assays, phosphorylation assays (Akt, Erk), specific antagonist treatment, in vivo lymphangiogenesis model, orthotopic breast cancer model with anti-CXCL12 antibody treatment\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo mechanistic experiments with pathway inhibitors in a single lab\",\n      \"pmids\": [\"22932666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CXCR7/ACKR3 expressed on venule endothelium regulates circulating CXCL12 plasma levels; genetic deletion or pharmacological inhibition of CXCR7 caused pronounced increases in plasma CXCL12 levels and impaired leucocyte migration toward CXCL12.\",\n      \"method\": \"Genetic CXCR7 deletion, pharmacological CXCR7 inhibition, plasma CXCL12 ELISA, leucocyte migration assay, immunohistochemistry, complementary protein detection techniques in human and mouse tissues\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological approaches with functional readout, replicated across species and tissues in a single study\",\n      \"pmids\": [\"24116850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CXCL12 regulates angiogenesis through CXCR4 via mTORC2 (but not mTORC1); CXCR4 signaling activates mTORC2 through a G-protein- and PI3K-dependent pathway as indicated by Akt Ser473 phosphorylation; mTORC2-dependent glycolytic regulator PFKFB3 is required for microvascular sprouting.\",\n      \"method\": \"mTOR complex-specific siRNA knockdown, pharmacological inhibition, Akt phosphorylation assays, 3D in vitro angiogenesis model, mouse tumor angiogenesis model\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple independent siRNAs and drugs targeting mTOR complexes with in vitro and in vivo confirmation in a single lab\",\n      \"pmids\": [\"27106789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Crystal structure of hu30D8 Fab/CXCL12α complex combined with mutational analysis revealed that residues Asn44/Asn45 of CXCL12α and part of the RFFESH region are a 'hot spot' required for CXCL12α binding to both CXCR4 and CXCR7.\",\n      \"method\": \"X-ray crystallography (Fab/CXCL12α complex), site-directed mutagenesis, cell surface binding assay, cell migration assay\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure plus mutagenesis identifying functional binding determinants, single lab but orthogonal structural and functional methods\",\n      \"pmids\": [\"23812669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Antitubulin chemotherapeutics (paclitaxel/vincristine) increase CXCL12 expression in spinal dorsal horn neurons via STAT3-p300 interaction: STAT3 phosphorylation increases its binding to the CXCL12 gene promoter and interaction with acetyltransferase p300, leading to enhanced histone H4 acetylation at the CXCL12 promoter and increased transcription; CXCL12 then signals via CXCR4 (not CXCR7) to potentiate nociceptive synaptic transmission.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), adeno-associated virus Cre-mediated STAT3 knockout, STAT3 inhibitor, siRNA, transgenic CXCL12 knockout mice, neutralizing antibody, electrophysiology (mEPSC recording), behavioral assays\",\n      \"journal\": \"Pain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reconstitution-level mechanistic dissection using CoIP, ChIP, genetics, pharmacology, and electrophysiology; multiple orthogonal methods in one study\",\n      \"pmids\": [\"28072604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCL12 acts via CXCR4 to activate the GSK3β/β-catenin(Thr120)/TCF21 signaling pathway, reducing TCF21-dependent transcription of ABCA1 and inhibiting ABCA1-mediated cholesterol efflux from macrophages; CXCR4 knockdown/inhibition blocked these effects.\",\n      \"method\": \"Luciferase reporter assay, chromatin immunoprecipitation, Western blotting (phospho-GSK3β, phospho-β-catenin), CXCR4 siRNA/inhibitor, cholesterol efflux assay, lentivirus CXCL12 overexpression in Apoe-/- mice\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase, ChIP, phosphorylation assays, receptor-specific knockdown, and in vivo confirmation in a single lab\",\n      \"pmids\": [\"31662443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Platelet-derived CXCL12 activates CXCR4 on platelets to trigger a signaling cascade involving Bruton's tyrosine kinase (Btk), leading to integrin αIIbβ3 activation, platelet aggregation, and granule release; platelet-specific CXCL12 deficiency in mice limits arterial thrombosis and neointimal lesion formation without increasing bleeding time.\",\n      \"method\": \"Platelet-specific CXCL12 knockout mice, CXCR4 inhibition, Btk phosphorylation assays, platelet aggregation assays under static and arterial flow conditions, carotid artery injury model, tail bleeding time assay, peptide (i[VREY]4) inhibition\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific knockout with defined in vivo thrombosis phenotype, mechanistic pathway defined by pharmacological and genetic approaches, multiple functional readouts\",\n      \"pmids\": [\"35313337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CXCL12 signaling through CXCR4 regulates the formation of productive immunological synapses in T cells; CXCR4 downregulation or blockade impairs actin polymerization at the T cell–APC contact site, alters MTOC polarization and IS structure, reduces T cell/APC contact duration and T cell activation (CD25, CD69, IL-2); this effect is mediated through Gi and JAK1/JAK2 kinases.\",\n      \"method\": \"CXCR4 siRNA knockdown, CXCR4 blocking antibody, confocal microscopy of actin and MTOC, flow cytometry (CD25, CD69), IL-2 mRNA measurement, pharmacological JAK1/2 inhibition\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (siRNA) and pharmacological approaches with multiple orthogonal functional readouts in a single lab\",\n      \"pmids\": [\"25917087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HMGB1 forms a heterocomplex with CXCL12 (reduced/all-thiol form) that signals via CXCR4 to recruit inflammatory cells; diflunisal binds directly to both HMGB1 and CXCL12 and disrupts this heterocomplex, specifically inhibiting the chemotactic activity of HMGB1 in vitro and in vivo without inhibiting TLR4-dependent (disulfide-HMGB1) responses.\",\n      \"method\": \"NMR binding assays, in vitro chemotaxis assays, in vivo inflammatory recruitment models, direct binding assays between diflunisal, HMGB1, and CXCL12\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural binding data plus in vitro and in vivo functional validation of heterocomplex disruption; multiple orthogonal methods in one study\",\n      \"pmids\": [\"31418171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CXCL12 rescues synaptodendritic spine density and cognitive flexibility via CXCR4-dependent stimulation of the Rac1/PAK actin polymerization pathway in layer II/III pyramidal neurons of the medial prefrontal cortex; CXCL12 preferentially regulates plastic thin spines.\",\n      \"method\": \"Rodent model of neuroinflammation (HAND), intracranial CXCL12 administration, CXCR4 antagonist treatment, confocal imaging of dendritic spines, Rac1/PAK pathway inhibition, behavioral cognitive flexibility assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo model with receptor-specific antagonism and pathway inhibition; single lab with multiple functional readouts\",\n      \"pmids\": [\"31971513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CXCL12/SDF-1 facilitates optic nerve regeneration in mature retinal ganglion cells (RGCs) via CXCR4-dependent stimulation of the PI3K/AKT/mTOR pathway (not JAK/STAT3); CXCL12 exerts disinhibitory effects toward myelin that are blocked by a CXCR4 antagonist or PI3K/mTOR inhibition.\",\n      \"method\": \"In vitro RGC neurite growth assay on laminin and myelin, CXCR4 antagonist treatment, PI3K/mTOR pathway inhibitors, JAK/STAT3 inhibitors, intravitreal CXCL12 injection, in vivo optic nerve crush model, mTOR activity assay\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo experiments with receptor-specific and pathway-specific pharmacological tools; single lab\",\n      \"pmids\": [\"23578489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CXCL12/CXCR4 autocrine signaling in esophageal cancer stem cells activates the ERK1/2 pathway to maintain high invasion and metastasis capacity; loss-of-function (shRNA, inhibitors) and gain-of-function strategies both confirmed CXCL12's role.\",\n      \"method\": \"CXCR4 shRNA knockdown, CXCR4 inhibitors, CXCL12 loss-of-function and gain-of-function, ERK1/2 phosphorylation assay, in vitro invasion/migration assays, in vivo metastasis model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — complementary loss- and gain-of-function with pathway readout in vitro and in vivo; single lab\",\n      \"pmids\": [\"28193907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CXCL12/CXCR4 axis induces glioma cell invadopodia formation and invasion by stimulating Arg kinase (ABL2)-mediated phosphorylation of cortactin at Y421; Arg silencing blocked CXCL12-induced cortactin phosphorylation and invadopodium formation, and CXCL12 could not induce invasion in Arg-knockdown cells.\",\n      \"method\": \"Arg siRNA knockdown, cortactin phosphorylation assay, co-immunoprecipitation of Arg and cortactin, invadopodia formation assay, invasion assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with multiple functional readouts (phosphorylation, invadopodia, invasion) and CoIP; single lab\",\n      \"pmids\": [\"32035133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In zebrafish, a single amino acid exchange distinguishes two Cxcl12 paralogs by determining their differential affinity for duplicated Cxcr4 receptors, establishing the molecular basis for primordial germ cell (PGC) preferential migration toward one paralog; this represents protein subfunctionalization via receptor-ligand affinity.\",\n      \"method\": \"Zebrafish genetics, site-directed mutagenesis of CXCL12 paralogs, PGC migration assays, receptor binding/affinity measurements\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis identifying single amino acid determinant of receptor selectivity with in vivo functional validation; single lab\",\n      \"pmids\": [\"21693511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Oncogenic JAK2 cooperates with CXCL12/CXCR4 signaling to enhance chemotactic responses in hematopoietic cells through increased PI3K signaling; JAK2 inhibition reduces CXCL12/CXCR4-induced chemotaxis, and primary myelofibrosis patient cells show increased CXCL12-induced chemotaxis compared to controls.\",\n      \"method\": \"MPL-W515L expression, JAK2 siRNA knockdown, JAK2 chemical inhibitors, chemotaxis assays with human cell lines and primary CD34+ cells from MPN patients, PI3K pathway readouts\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological convergence on pathway with primary patient cell validation; single lab\",\n      \"pmids\": [\"28903325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CXCL12 (SDF-1) induces CD9 tetraspanin expression in satellite cell-derived myoblasts, bone marrow-derived mesenchymal stem cells, and embryonic stem cells through CXCR4 (not CXCR7); CXCR4 silencing blocked the CD9 upregulation effect, and CD9 upregulation enhances cell migration and fusion with myoblasts during muscle regeneration.\",\n      \"method\": \"In vivo skeletal muscle injury model (rat and Pax7-/- mice), CXCR4/CXCR7 siRNA knockdown, flow cytometry for CD9, in vitro migration and fusion assays with multiple stem cell types\",\n      \"journal\": \"Stem cell research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-specific siRNA with in vitro and in vivo validation across multiple cell types; single lab\",\n      \"pmids\": [\"25890097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CXCL12-secreting senescent fibroblasts (p16high) in aged bladder accumulate as cancer-associated fibroblasts and promote tumor growth; CXCL12 secreted by these cells inhibits CD8+ naïve T cell differentiation into cytotoxic T cells and attracts MDSCs, creating an immunosuppressive tumor microenvironment; elimination of p16high cells or CXCL12 inhibition suppressed tumor growth in vivo.\",\n      \"method\": \"Genetically modified mouse models (p16-reporter), single-cell RNA sequencing, p16high cell elimination, CXCL12 signaling inhibition, humanized mouse HCC model, bispecific antibody (anti-CXCL12/PD1)\",\n      \"journal\": \"Nature aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic and pharmacological interventions with mechanistic scRNA-seq; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"39251867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CXCL12 has structurally distinct binding sites for its receptor CXCR4 and for glycosaminoglycans (heparan sulfate); these sites do not overlap, and different CXCL12 isoforms display different GAG-binding abilities, suggesting GAG binding positions CXCL12 in tissues to maintain haptotactic gradients while leaving the receptor-binding domain free.\",\n      \"method\": \"Structural analysis, NMR mapping of GAG-binding and receptor-binding epitopes, isoform-specific binding assays\",\n      \"journal\": \"Carbohydrate research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural mapping with functional binding assays for receptor vs. GAG sites; review-style paper but cites direct structural evidence\",\n      \"pmids\": [\"18334249\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CXCL12 (SDF-1/PBSF) is a constitutively expressed CXC chemokine that signals primarily through the G-protein-coupled receptor CXCR4 and the atypical scavenger receptor CXCR7/ACKR3 to regulate cell migration, survival, and development; CXCR4 activates divergent intracellular cascades including Gαi-dependent signaling (calcium flux, chemotaxis), PI3K/Akt/mTOR, ERK1/2, JAK/STAT, PAK-p38α-MAPKAP-K2-HSP27, Rac1/PAK actin polymerization, and Btk-integrin αIIbβ3 pathways depending on cellular context; CXCR7 constitutively internalizes and degrades CXCL12 to regulate its extracellular availability and can heterodimerize with CXCR4 to dampen Gαi signaling; CXCL12's activity is further regulated by binding to glycosaminoglycans via a site distinct from its receptor-binding domain, by post-translational modifications (proteolysis, citrullination, nitration), and by promoter methylation; in development, CXCL12/CXCR4 signaling is essential for B lymphopoiesis, bone-marrow myelopoiesis, cardiogenesis, and neuronal migration, as established by knockout mouse phenotypes.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CXCL12 (SDF-1/PBSF) is a constitutively secreted chemokine that orchestrates cell migration, survival, and tissue development, established by germline knockout mice that die perinatally with defective B-cell lymphopoiesis, bone-marrow myelopoiesis, and cardiac ventricular septation [#0]. Its signaling output is determined by two receptors: the G-protein-coupled receptor CXCR4 transduces directional and proliferative signals, while the atypical receptor CXCR7/ACKR3 shapes ligand availability—it constitutively internalizes and degrades CXCL12 without ligand saturation [#2], regulates circulating plasma CXCL12 levels through venular endothelium [#6], and heterodimerizes with CXCR4 to impair Gαi activation and calcium responses, dampening chemotaxis [#1]. Through CXCR4, CXCL12 engages context-dependent intracellular cascades that converge on cytoskeletal and survival machinery: a PAK1/2→p38α→MAPKAP-K2→HSP27 axis required for migration [#3], Rac1/PAK-driven actin polymerization controlling dendritic spine plasticity [#14], ABL2(Arg)-mediated cortactin Y421 phosphorylation driving invadopodia and invasion [#17], PI3K/AKT/mTOR signaling promoting neurite regeneration and mTORC2-dependent angiogenesis [#15, #7], ERK1/2 supporting cancer-stem-cell invasion and lymphangiogenesis [#16, #5], JAK/Gi-dependent immunological synapse formation in T cells [#12], and Btk-driven integrin αIIbβ3 activation underlying platelet aggregation and arterial thrombosis [#11]. CXCL12 activity is further tuned by structural and transcriptional regulation: distinct, non-overlapping receptor-binding and glycosaminoglycan-binding surfaces allow GAGs to anchor haptotactic gradients in tissue while leaving the receptor epitope free [#22], an Asn44/Asn45–RFFESH 'hot spot' governs binding to both CXCR4 and CXCR7 [#8], promoter DNA methylation and STAT3-p300-driven histone acetylation control its expression [#4, #9], and it can form a chemotactic heterocomplex with reduced HMGB1 that signals through CXCR4 [#13]. In disease contexts these mechanisms drive rheumatoid synovial MMP expression [#4], atherosclerotic suppression of macrophage cholesterol efflux [#10], chemotherapy-induced nociception [#9], and senescent-fibroblast-mediated tumor immunosuppression [#21].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established that CXCL12 is non-redundantly required for development, defining its core physiological roles before its receptors and signaling were dissected.\",\n      \"evidence\": \"Germline knockout mouse with histological and progenitor analyses\",\n      \"pmids\": [\"8757135\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the receptor mediating each phenotype\", \"Cell-autonomous versus niche contributions not resolved\", \"Downstream signaling cascades undefined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Resolved how CXCL12 is positioned in tissue versus how it engages its receptor, showing receptor-binding and glycosaminoglycan-binding surfaces are structurally separable.\",\n      \"evidence\": \"NMR epitope mapping and isoform-specific GAG-binding assays\",\n      \"pmids\": [\"18334249\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo contribution of GAG anchoring to gradient formation not directly tested here\", \"Functional consequence of isoform-specific GAG affinity differences incomplete\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined a discrete kinase cascade linking CXCL12 stimulation to the actin/migration machinery, moving beyond Gαi/calcium readouts.\",\n      \"evidence\": \"p38α knockout mice, RNAi of MAPKAP-K2/HSP27, and pharmacological inhibition in migration assays\",\n      \"pmids\": [\"16574378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor (CXCR4 vs CXCR7) upstream of PAK not specified\", \"Direct HSP27 effector targets on the cytoskeleton not mapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Explained how CXCR7 modulates CXCR4 output, demonstrating constitutive heterodimerization that conformationally suppresses Gαi activation and chemotaxis.\",\n      \"evidence\": \"BRET/FRET, calcium flux, and chemotaxis assays in T cells and transfected lines\",\n      \"pmids\": [\"19380869\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of heterodimers in native cells unclear\", \"In vivo relevance of dimer-mediated dampening not established here\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Reframed CXCR7 as a scavenger that controls CXCL12 abundance, distinguishing ligand availability regulation from classical signaling.\",\n      \"evidence\": \"Internalization, degradation, and cycling assays across cell lines, mouse tissue, and zebrafish\",\n      \"pmids\": [\"20161793\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trafficking adaptors mediating CXCR7 cycling not identified\", \"Quantitative impact on tissue gradients not measured\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated promoter DNA hypomethylation as a transcriptional driver of pathological CXCL12 expression and assigned a CXCR7-dependent downstream effect.\",\n      \"evidence\": \"Bisulfite sequencing, demethylation treatment, and receptor-specific siRNA in rheumatoid synovial fibroblasts\",\n      \"pmids\": [\"21753787\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Methyltransferase/demethylase responsible not identified\", \"CXCR7-to-MMP signaling intermediates undefined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established the molecular basis of CXCL12 paralog/receptor selectivity, showing a single residue tunes affinity to direct germ cell migration.\",\n      \"evidence\": \"Zebrafish genetics, site-directed mutagenesis, and PGC migration/affinity assays\",\n      \"pmids\": [\"21693511\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generalizability of the affinity rule to mammalian isoforms not tested\", \"Structural basis of the affinity shift not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified the shared CXCL12 surface engaging both receptors, locating Asn44/Asn45 and RFFESH as the binding hot spot.\",\n      \"evidence\": \"X-ray crystallography of a Fab/CXCL12α complex with mutagenesis and binding/migration assays\",\n      \"pmids\": [\"23812669\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not explain receptor selectivity since the site is shared\", \"Conformational differences between CXCR4 and CXCR7 engagement unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Linked CXCL12/CXCR4 to neuronal regeneration through a specific PI3K/AKT/mTOR route, excluding JAK/STAT3.\",\n      \"evidence\": \"RGC neurite assays on myelin, receptor and pathway inhibitors, and an in vivo optic nerve crush model\",\n      \"pmids\": [\"23578489\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"mTOR complex specificity not distinguished here\", \"Disinhibition mechanism toward myelin not molecularly defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed CXCL12/CXCR4 shapes the T cell immunological synapse via Gi/JAK-dependent actin and MTOC organization, connecting the chemokine to adaptive immune activation.\",\n      \"evidence\": \"CXCR4 siRNA/blockade, confocal imaging, flow cytometry, and JAK inhibition in T cells\",\n      \"pmids\": [\"25917087\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct JAK substrates at the synapse not identified\", \"Physiological in vivo consequence for T cell responses not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected CXCL12/CXCR4 signaling to a tetraspanin (CD9) program promoting myoblast migration and fusion in muscle regeneration.\",\n      \"evidence\": \"Muscle injury models, receptor-specific siRNA, and migration/fusion assays across stem cell types\",\n      \"pmids\": [\"25890097\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling steps linking CXCR4 to CD9 transcription unmapped\", \"Whether CD9 is necessary for the in vivo regenerative phenotype unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined the mTOR complex specificity of CXCL12-driven angiogenesis, showing mTORC2/PFKFB3 glycolytic control of sprouting.\",\n      \"evidence\": \"Complex-specific siRNA, pharmacology, Akt-Ser473 readout, and 3D/in vivo angiogenesis models\",\n      \"pmids\": [\"27106789\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Link between mTORC2 and PFKFB3 induction not mechanistically detailed\", \"Endothelial versus tumor cell source of signal not separated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed oncogenic JAK2 amplifies CXCL12/CXCR4 chemotaxis via PI3K, providing a disease context for enhanced responsiveness in myeloproliferative neoplasms.\",\n      \"evidence\": \"MPL-W515L expression, JAK2 knockdown/inhibition, and chemotaxis of patient CD34+ cells\",\n      \"pmids\": [\"28903325\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical interaction between JAK2 and CXCR4 signaling not demonstrated\", \"Receptor-level mechanism of sensitization unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Uncovered transcriptional induction of CXCL12 by chemotherapy through STAT3-p300 histone acetylation, linking it to neuropathic pain via CXCR4-potentiated synaptic transmission.\",\n      \"evidence\": \"CoIP, ChIP, STAT3 genetics/inhibition, CXCL12 knockout, and electrophysiology in spinal neurons\",\n      \"pmids\": [\"28072604\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CXCR4 downstream effectors potentiating mEPSCs not detailed\", \"Generalizability beyond antitubulin agents untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established autocrine CXCL12/CXCR4/ERK1/2 signaling as a driver of cancer-stem-cell invasion and metastasis.\",\n      \"evidence\": \"Loss- and gain-of-function with ERK readout in vitro and in vivo metastasis model\",\n      \"pmids\": [\"28193907\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"ERK downstream invasion effectors not identified\", \"Contribution of CXCR7 not assessed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a platelet-intrinsic CXCL12/CXCR4/Btk→integrin αIIbβ3 cascade controlling thrombosis without affecting hemostasis.\",\n      \"evidence\": \"Platelet-specific CXCL12 knockout, Btk phosphorylation, aggregation under flow, and carotid injury model\",\n      \"pmids\": [\"35313337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Source of CXCL12 acting in trans versus cis not fully resolved\", \"Coupling between Btk and integrin inside-out signaling not detailed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed CXCL12/CXCR4 suppresses macrophage cholesterol efflux through a GSK3β/β-catenin/TCF21→ABCA1 transcriptional axis, implicating it in atherosclerosis.\",\n      \"evidence\": \"Luciferase, ChIP, phospho-immunoblotting, receptor knockdown, and Apoe-/- in vivo overexpression\",\n      \"pmids\": [\"31662443\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct CXCR4-to-GSK3β coupling mechanism not shown\", \"Relative contribution to plaque burden quantitatively limited\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated CXCL12 forms a functional heterocomplex with reduced HMGB1 that enhances CXCR4-dependent inflammatory recruitment, defining a druggable composite chemoattractant.\",\n      \"evidence\": \"NMR binding, chemotaxis, and in vivo recruitment with diflunisal disruption\",\n      \"pmids\": [\"31418171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of heterocomplex-CXCR4 engagement not resolved\", \"Endogenous regulation of the complex in vivo unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Linked CXCL12/CXCR4 to synaptic plasticity via Rac1/PAK actin polymerization, showing it restores dendritic spines and cognitive flexibility.\",\n      \"evidence\": \"Neuroinflammation model, intracranial CXCL12, CXCR4 antagonism, pathway inhibition, and spine imaging\",\n      \"pmids\": [\"31971513\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link from CXCR4 to Rac1 activation not detailed\", \"Specificity for thin spines mechanistically unexplained\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified ABL2(Arg)-mediated cortactin Y421 phosphorylation as the mechanism for CXCL12/CXCR4-driven invadopodia formation in glioma.\",\n      \"evidence\": \"Arg siRNA, cortactin phosphorylation, CoIP, and invadopodia/invasion assays\",\n      \"pmids\": [\"32035133\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How CXCR4 activates Arg kinase not defined\", \"In vivo invasion contribution not tested here\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected senescent-fibroblast-derived CXCL12 to tumor immunosuppression, showing it blocks CD8 T cell differentiation and recruits MDSCs.\",\n      \"evidence\": \"p16-reporter mice, scRNA-seq, senescent-cell elimination, CXCL12 inhibition, and bispecific anti-CXCL12/PD1 antibody\",\n      \"pmids\": [\"39251867\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor (CXCR4 vs CXCR7) on T cells/MDSCs not specified\", \"Direct signaling pathway in target immune cells undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the shared Asn44/Asn45-RFFESH binding hot spot produces distinct signaling versus scavenging outcomes at CXCR4 versus CXCR7, and how post-translational modifications and GAG anchoring quantitatively shape gradients in vivo, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model distinguishing CXCR4 versus CXCR7 engagement of the shared epitope\", \"Quantitative in vivo contribution of GAG binding and proteolytic/citrullination modifications to gradient formation not established\", \"Receptor identity unassigned in several disease contexts\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [1, 8, 13, 18]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 3, 11, 12]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 6, 13]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 3, 7, 11, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 12, 21]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 18, 20]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [1, 2]}\n    ],\n    \"complexes\": [\n      \"CXCL12–CXCR4 (heterodimer with CXCR7/ACKR3)\",\n      \"CXCL12–HMGB1 heterocomplex\"\n    ],\n    \"partners\": [\n      \"CXCR4\",\n      \"CXCR7/ACKR3\",\n      \"HMGB1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}